Annual EBITDA
-$17.97 M
-$539.00 K-3.09%
01 December 2023
Summary:
TransCode Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$17.97 million, with the most recent change of -$539.00 thousand (-3.09%) on 01 December 2023. During the last 3 years, it has fallen by -$11.27 million (-168.02%). RNAZ annual EBITDA is now -3892.31% below its all-time high of -$450.20 thousand, reached on 31 December 2019.RNAZ EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$2.18 M
+$2.86 M+56.71%
01 September 2024
Summary:
TransCode Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$2.18 million, with the most recent change of +$2.86 million (+56.71%) on 01 September 2024. Over the past year, it has increased by +$1.75 million (+44.45%). RNAZ quarterly EBITDA is now -177.48% below its all-time high of $2.82 million, reached on 30 June 2021.RNAZ Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$14.33 M
+$2.96 M+17.12%
01 September 2024
Summary:
TransCode Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$14.33 million, with the most recent change of +$2.96 million (+17.12%) on 01 September 2024. Over the past year, it has increased by +$3.64 million (+20.26%). RNAZ TTM EBITDA is now -86761.21% below its all-time high of -$16.50 thousand, reached on 01 March 2020.RNAZ TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +44.5% | +20.3% |
| 3 y3 years | -168.0% | +21.2% | -113.7% |
| 5 y5 years | -3892.3% | - | - |
RNAZ EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -168.0% | at low | at high | +57.6% | -150.4% | +25.0% |
| 5 y | 5 years | -3892.3% | at low | -177.5% | +57.6% | <-9999.0% | +25.0% |
| alltime | all time | -3892.3% | at low | -177.5% | +57.6% | <-9999.0% | +25.0% |
TransCode Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.18 M(-56.7%) | -$14.33 M(-17.1%) |
| June 2024 | - | -$5.04 M(+58.8%) | -$17.29 M(+5.2%) |
| Mar 2024 | - | -$3.18 M(-19.2%) | -$16.45 M(-8.5%) |
| Dec 2023 | -$17.97 M(+3.1%) | -$3.93 M(-23.6%) | -$17.97 M(-5.9%) |
| Sept 2023 | - | -$5.14 M(+22.6%) | -$19.11 M(+4.8%) |
| June 2023 | - | -$4.20 M(-10.8%) | -$18.24 M(-2.4%) |
| Mar 2023 | - | -$4.70 M(-7.1%) | -$18.69 M(+7.2%) |
| Dec 2022 | -$17.43 M | -$5.06 M(+18.4%) | -$17.43 M(+15.1%) |
| Sept 2022 | - | -$4.27 M(-8.1%) | -$15.14 M(+14.8%) |
| June 2022 | - | -$4.65 M(+34.8%) | -$13.19 M(+130.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$3.45 M(+24.5%) | -$5.72 M(-14.7%) |
| Dec 2021 | -$6.71 M(+244.0%) | -$2.77 M(+19.3%) | -$6.71 M(+43.2%) |
| Sept 2021 | - | -$2.32 M(-182.4%) | -$4.68 M(+35.5%) |
| June 2021 | - | $2.82 M(-163.6%) | -$3.46 M(-45.7%) |
| Mar 2021 | - | -$4.43 M(+492.7%) | -$6.36 M(+226.5%) |
| Dec 2020 | -$1.95 M(+333.0%) | - | - |
| Dec 2020 | - | -$747.70 K(-31.6%) | -$1.95 M(+62.2%) |
| Sept 2020 | - | -$1.09 M(+1095.2%) | -$1.20 M(+1012.6%) |
| June 2020 | - | -$91.50 K(+454.5%) | -$108.00 K(+554.5%) |
| Mar 2020 | - | -$16.50 K | -$16.50 K |
| Dec 2019 | -$450.20 K | - | - |
FAQ
- What is TransCode Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly EBITDA year-on-year change?
- What is TransCode Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for TransCode Therapeutics?
- What is TransCode Therapeutics TTM EBITDA year-on-year change?
What is TransCode Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RNAZ is -$17.97 M
What is the all time high annual EBITDA for TransCode Therapeutics?
TransCode Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$450.20 K
What is TransCode Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RNAZ is -$2.18 M
What is the all time high quarterly EBITDA for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $2.82 M
What is TransCode Therapeutics quarterly EBITDA year-on-year change?
Over the past year, RNAZ quarterly earnings before interest, taxes, depreciation & amortization has changed by +$1.75 M (+44.45%)
What is TransCode Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RNAZ is -$14.33 M
What is the all time high TTM EBITDA for TransCode Therapeutics?
TransCode Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$16.50 K
What is TransCode Therapeutics TTM EBITDA year-on-year change?
Over the past year, RNAZ TTM earnings before interest, taxes, depreciation & amortization has changed by +$3.64 M (+20.26%)